Does Macular Degeneration Take All Your Sight? What It Spares and What It Threatens

A retired schoolteacher sits in a dim consulting room and asks the question she has been rehearsing all week: “Am I going to go blind?” The ophthalmologist has just told her that the smudge in the middle of her crossword, the one she blamed on cheap reading glasses, is early age-related macular degeneration. She has already pictured a white cane and a locked front door.

That picture is one of the most persistent macular degeneration myths, and it causes real harm. People delay appointments because they assume nothing can be done, or they stop driving, cooking and reading long before the disease requires it. The reality is both more hopeful and more complicated than the folklore suggests.

This explainer walks through what the condition actually attacks, what it almost always leaves alone, which treatments have evidence behind them, and which comforting or frightening stories deserve to be retired. Every decision about your own eyes, of course, belongs with the team examining them.

What does macular degeneration actually do to your eyesight?

Start with the geography of the eye. The retina is the light-sensitive lining at the back of the eyeball, roughly the size of a postage stamp. Near its center sits the macula, a patch about 5 millimeters across that is packed with cone cells, the photoreceptors responsible for sharp, detailed, color vision. Everything you point your eyes at, from a street sign to a grandchild’s face, lands on the macula.

Age-related macular degeneration, usually shortened to AMD, is a slow deterioration of this patch. In its common early form, waste deposits called drusen build up under the retina, and the layer of support cells beneath the photoreceptors starts to thin. Think of the macula as a very fine camera sensor with a few dead pixels in the center: the edges of the image stay crisp, but the middle develops a soft, distorted or missing area.

The National Eye Institute, part of the NIH, describes AMD as a leading cause of vision loss in people over 50, and notes that it affects central vision specifically. That distinction matters more than any other fact in this article. The peripheral retina, the vast majority of the surface area, uses different cells and a different blood supply, and AMD does not usually involve it.

Early changes are often so subtle that people notice nothing at all; the condition is frequently picked up at a routine eye examination when the clinician sees drusen on the retina. Later, straight lines may look wavy, print may seem faded or need brighter light, and a small gray or blank spot may appear in the center of vision. How far that progression goes, and how fast, varies widely from one person to the next.

Does macular degeneration cause blindness? What it spares

The honest answer is that AMD threatens central vision and usually spares side vision, which is why clinicians rarely use the word “blind” when describing it. The NHS states plainly that AMD does not cause total blindness, though it can make everyday activities such as reading and recognizing faces difficult.

Picture someone with advanced AMD in both eyes looking at a friend across a table. The friend’s face may be a blur or a blank, yet the person can see the friend’s hands, the shape of the chair and the window behind them. They can walk across the room without bumping into furniture. They may struggle to read a menu but can tell where the plate is. Legally, someone with severe central loss may meet the definition of “sight impaired” or “severely sight impaired” because those definitions rest heavily on central acuity, which is where the confusion with blindness arises.

What AMD does not do is also worth spelling out. It does not cause pain. It does not make the eye look different from the outside. It does not spread to other parts of the body, and it does not cause the eye to stop registering light. Nor does using your eyes wear them out faster; reading, screens and close work do not accelerate the disease, a point both the Mayo Clinic and the NHS make.

Two caveats keep this balanced. First, the two eyes do not always progress in step, and the better eye often compensates so well that damage in the other goes unnoticed, which is why clinicians ask people to test one eye at a time. Second, central vision is what most of us value most, so “spared peripheral vision” is reassuring but not a reason to dismiss the condition.

How many people have macular degeneration?

It is common enough that most extended families include someone living with it. The National Eye Institute identifies AMD as a leading cause of vision loss among older adults in the United States, and widely cited US estimates put the number of adults with some form of the condition at roughly 20 million, the great majority in the early stage where vision is normal or nearly so. The NHS describes it as a common condition that usually first affects people in their 50s and 60s.

Those headline numbers hide an important shape. Most people counted have early AMD, which means drusen and pigment changes seen by a clinician but little or no effect on daily life. A much smaller group has late AMD, the stage at which central vision is meaningfully reduced. Prevalence climbs steeply with age: the condition is uncommon before 50 and considerably more frequent after 75, a pattern consistent across the NEI, Mayo Clinic and NHS descriptions.

Why does this matter for a reader worried about their own eyes? Because “a diagnosis of AMD” and “losing vision from AMD” are not the same event. A person told at 62 that they have early drusen may never progress to the late stage; the condition is monitored precisely because progression is possible, not inevitable.

Population aging means the absolute number of people affected is expected to rise in most high-income countries, which is one reason eye-health bodies emphasize routine examinations after 50. An examination that finds early changes is not bad news so much as useful information: it starts the monitoring that catches treatable change early.

Wet vs dry macular degeneration: what the labels really mean

The words “wet” and “dry” confuse almost everyone at first, partly because they have nothing to do with tears or dry eye. They describe what is happening under the retina.

Dry AMD is the slow form. Drusen accumulate, the retinal pigment epithelium (the nourishing layer under the photoreceptors) thins, and in its late stage patches of cells die off, a change called geographic atrophy because the dead areas look like continents on a map. The Mayo Clinic notes that dry AMD accounts for most cases and typically progresses over years.

Wet AMD is the faster, more aggressive form. Abnormal new blood vessels grow from the layer beneath the retina, a process called choroidal neovascularization. These vessels are fragile, leak fluid and blood, and can scar the macula. Wet AMD is responsible for a disproportionate share of severe central vision loss, and it can change vision over weeks rather than years. Crucially, it is the form that current injectable treatments target.

Feature	Dry (atrophic) AMD	Wet (neovascular) AMD
Share of cases	Most people with AMD	A minority of cases
What happens	Drusen build-up, thinning, cell loss	Leaky new blood vessels under the retina
Typical pace	Slow, over years	Can be rapid, over weeks to months
Main threat	Gradual central fading, geographic atrophy	Sudden distortion, bleeding, scarring
Established treatment	Monitoring; certain supplement formulas at intermediate stage	Anti-VEGF injections into the eye

One more point corrects a common assumption: the two are not separate diseases. Wet AMD develops in eyes that already have dry changes, which is why someone with “only” dry AMD is asked to watch for new distortion. The dry form can convert; the conversion is the moment treatment becomes urgent.

Who usually develops it, and who is asked to watch and wait

Age is the dominant risk factor; the condition is named for it. Beyond age, the National Eye Institute lists smoking, a family history of AMD, and being of European ancestry as factors that raise risk, and the Mayo Clinic adds cardiovascular disease and obesity to the list. Smoking stands out because it is both powerful and modifiable: the NEI states that smoking roughly doubles the risk of developing AMD.

Clinicians stage the disease rather than simply diagnosing it. Early AMD means small or medium drusen without vision change. Intermediate AMD means larger drusen or pigment changes, often still with good acuity. Late AMD means either geographic atrophy or wet disease. The stage determines what happens next, and for many people the recommendation is monitoring rather than intervention.

“Watch and wait” frustrates patients, who understandably want something done. The reasoning is evidence-based. No treatment has been shown to reverse early drusen, and injections carry small but real risks that are not justified when there is no leakage to treat. What monitoring offers is timing: regular examinations with optical coherence tomography (a painless scan that images retinal layers in cross-section) can catch the transition to wet disease before scarring sets in.

People at the intermediate stage are the group for whom the AREDS2 supplement formula has evidence, discussed in the nutrition section below. People with late disease in one eye are monitored closely in the other, because the second eye carries a higher chance of following. And people with early changes are typically asked to stop smoking, keep blood pressure controlled, eat a diet rich in leafy greens and fish, and return at the interval the clinician sets.

None of these categories is fixed. Someone can move from monitoring to treatment within a single appointment if a scan shows fluid. That is precisely why the appointments matter.

Why are carrots good for your eyes, and are they?

The carrot story deserves its own section because it is the most widely believed eye myth of all, and it is roughly one-quarter true.

The true part: carrots are rich in beta-carotene, which the body converts to vitamin A, and vitamin A is essential for the light-sensing pigment in rod cells. The NIH Office of Dietary Supplements notes that vitamin A deficiency is a cause of night blindness and, in severe cases, permanent eye damage. In a population short of vitamin A, carrots genuinely protect sight.

The false part: in a person who is already getting enough vitamin A, which describes most people eating a varied diet in high-income countries, extra carrots do not sharpen vision, do not prevent the need for glasses and do not stop macular degeneration. The body does not store improved eyesight the way it stores fat. A popular wartime tale credits British propaganda with exaggerating carrots’ powers to disguise the use of radar; whatever its origins, the belief outlived the war by eighty years.

Here the story turns ironic. The large NIH-funded AREDS trials tested a supplement formula containing beta-carotene and found it reduced progression from intermediate to late AMD. The follow-up AREDS2 trial then replaced beta-carotene with lutein and zeaxanthin, two pigments concentrated in the macula and found in kale, spinach and corn. The reason, per the National Eye Institute, was that high-dose beta-carotene had been linked to increased lung cancer risk in people who smoked or had recently quit. The orange vegetable’s signature nutrient was, for a specific group, the wrong ingredient.

What survives this myth-busting is sensible: a diet rich in dark leafy greens, colorful vegetables and oily fish is associated with lower AMD risk in observational studies cited by the Mayo Clinic. Carrots are welcome on the plate. They are just not a treatment.

Is macular degeneration hereditary? What the genes do and don't decide

Family history matters, and this is one area where the folklore undersells the evidence rather than overselling it. The National Eye Institute lists a family history of AMD among the established risk factors, and researchers have identified more than twenty genetic variants associated with the condition. The two most studied sit in a gene for complement factor H, part of the immune system’s inflammatory machinery, and in a region called ARMS2. Together they explain a substantial share of inherited risk.

What the genes do not do is write a script. Having a parent or sibling with AMD raises your probability of developing it; it does not guarantee it, and plenty of people with late AMD have no known affected relatives. Genetics interacts with environment, and the strongest environmental lever, smoking, appears to multiply inherited risk rather than simply add to it.

A practical question follows: should people with a family history get genetic testing? Mainstream eye-health bodies do not currently recommend routine genetic testing for AMD, because the result would not change what a clinician advises. The advice for someone at elevated genetic risk is the same as for anyone else over 50: do not smoke, eat well, control cardiovascular risk factors, and have regular dilated eye examinations. Knowing a variant status does not alter the monitoring interval or the treatment threshold.

Inheritance also explains a pattern families notice. If one person developed wet AMD in their late 60s, their siblings sometimes report early drusen around the same age. That is a reason for the siblings to be examined, not a reason for alarm. Early drusen in a 60-year-old with a strong family history is exactly the scenario in which monitoring earns its keep.

Can macular degeneration be stopped? What treatment actually does

No treatment restores a macula to the way it was before the disease, and anyone promising that is selling something. What established treatment can do is slow or halt further damage, and in wet AMD it can sometimes recover vision lost to recent fluid.

The mainstay for wet AMD is a class of medicines called anti-VEGF agents. VEGF, vascular endothelial growth factor, is the signaling protein that tells blood vessels to grow and leak; the abnormal vessels in wet AMD depend on it. Anti-VEGF medicines are injected into the jelly of the eye under local anesthetic drops, where they bind VEGF and switch off the signal. The leaking vessels shrink, fluid clears and the retina flattens. The NHS describes this as a treatment that can stop vision getting worse and, in some cases, improve it, with injections given regularly rather than once.

Timelines are the part patients find hardest. Because the medicine is cleared from the eye over weeks, injections are typically given monthly at first and then at intervals set by the response seen on scans; the NHS notes that treatment is usually ongoing. The ophthalmologist decides frequency, and no explainer can substitute for that judgment.

Photodynamic therapy, which uses a light-activated drug to seal vessels, is now used only in specific situations. For dry AMD, the picture is thinner: the AREDS2 formula is the evidence-based option at the intermediate stage, and the NEI reports it lowered the risk of progression to late AMD by about 25 percent over five years in the trial population. Newer injectable medicines for geographic atrophy exist in some countries; their role is still being defined, and the discussion belongs with a retina specialist.

Laser “zapping” of drusen, eye exercises, herbal eye drops and unregulated “vision supplements” have no evidence of benefit for AMD and are not recommended by any mainstream body.

What the first weeks after a diagnosis usually look like

The appointment itself tends to be longer than people expect. Pupils are dilated with drops, which blur near vision for several hours and make bright light uncomfortable, so most people are advised not to drive home. The clinician examines the retina, and in most modern clinics an OCT scan is taken; if wet disease is suspected, a dye test called fluorescein angiography may be added to map leaking vessels.

For dry or early disease, the weeks that follow are quiet. The main homework is self-monitoring, often with an Amsler grid, a square of fine lines with a central dot. Looked at one eye at a time, with reading glasses if needed, the grid should appear straight and complete; wavy, missing or blurred areas are the signal to call. The NHS and Mayo Clinic both describe this kind of home checking as a way to detect change between appointments, not as a diagnostic test.

For wet disease, treatment usually starts quickly, often within days to a couple of weeks of diagnosis, because scarring from untreated leakage is permanent. The injection appointment is brief. Eyes are numbed and cleaned with an antiseptic, a small clip holds the lids, and the injection takes seconds. Afterward, a gritty feeling, redness at the injection site and a few floating specks in the vision are common and typically settle within a day or two. Vision may be blurry for the rest of the day.

Follow-up scans at each visit show whether fluid is clearing. Some people notice improvement within the first month or two; others stabilize without improving. Either outcome is considered a success relative to the natural course of untreated wet AMD, and expectations are best set by the treating team, who can see the individual scan.

Smoking, blood pressure and the lifestyle factors with real evidence

Advice about “lifestyle” often dissolves into vagueness, so it is worth separating the factors with solid evidence from the ones that merely sound plausible.

Smoking sits at the top with the strongest data. The National Eye Institute states that smoking roughly doubles the risk of AMD, and the association holds across multiple large cohorts. Stopping reduces risk over time, though former smokers remain at somewhat higher risk than people who never smoked. If a person with early AMD asks what single change matters most, the evidence-based answer is this one.

Cardiovascular health comes next. The Mayo Clinic lists high blood pressure, high cholesterol and obesity as risk factors, which fits the biology: the macula is one of the most metabolically active tissues in the body and depends on a dense bed of small blood vessels. Managing these factors is advised for general health and may also matter for the retina, though the evidence is weaker than for smoking.

Diet has consistent observational support. People who eat more dark leafy greens, oily fish and nuts tend to have lower rates of advanced AMD in studies cited by the NEI and Mayo Clinic. Observational does not prove causation, but the pattern is coherent enough that most clinicians recommend it.

Then there are the factors with little or no evidence. Sunlight exposure has been studied extensively with inconclusive results; sunglasses are reasonable for comfort and for other eye conditions, but they are not an AMD treatment. Screen time, reading in dim light and “eye strain” have no demonstrated link to AMD progression; the NHS is explicit that using your eyes does not damage them. Blue-light filtering lenses have not been shown to prevent or slow the disease. Spending money on them in the hope of protecting the macula is spending on a myth.

What people often get wrong: macular degeneration myths, corrected

Some myths soothe and some frighten; both can lead to poor decisions. Here are the ones clinicians hear most often, set against the evidence.

• “It means I will go blind.” AMD affects central vision; peripheral vision is usually preserved, and the NHS states it does not cause total blindness.
• “Nothing can be done, so why bother with appointments?” Wet AMD is treatable with anti-VEGF injections, and the window for preventing permanent scarring is measured in weeks. Monitoring is the whole point of the appointments.
• “If my vision is fine, my eyes are fine.” The better eye compensates. Many people discover significant loss in one eye only when they happen to cover the other.
• “Reading and screens make it worse.” They do not; using the eyes does not accelerate retinal cell loss.
• “Carrots or vision supplements will fix it.” Only a specific formula, at a specific stage, has trial evidence, and it slows progression rather than restoring sight. The NEI’s AREDS pages spell out who was studied.
• “Injections into the eye are agonizing and dangerous.” The eye is numbed; most people describe pressure rather than pain. Serious complications such as infection inside the eye are uncommon, which is why the risk is accepted when leakage is present and not before.
• “Dry AMD is the harmless kind.” It is slower, not harmless. Late dry AMD, geographic atrophy, can erode central vision substantially, and dry can convert to wet.
• “Only very old people get it.” Early changes commonly appear in the 50s and 60s, which is when monitoring is most useful.

A final one is subtler. People sometimes believe a diagnosis of AMD means they should stop driving, cooking or living alone immediately. The appropriate time for each of those changes depends on measured vision, not on the label, and a low-vision assessment can help families make those calls on evidence rather than fear.

Is macular degeneration ever misdiagnosed? The other eye conditions that start with "M"

Yes, in both directions, and the reason is anatomical: several unrelated conditions produce distortion or a central blur because they all disturb the same small patch of retina. People searching for “the eye condition that starts with M” often land on macular degeneration when the clinician actually said something else.

Macular edema is swelling of the macula from fluid leakage, most often caused by diabetes or a blocked retinal vein. It distorts vision much as wet AMD does but has different causes and treatments. A macular hole is a small full-thickness defect in the center of the macula, often age-related, usually treated with surgery rather than injections. Central serous chorioretinopathy, which causes a blister of fluid under the macula, tends to affect younger adults and often resolves on its own; it is a classic look-alike for wet AMD. Myopic degeneration occurs in people with very high short-sightedness and can produce drusen-like changes and even neovascularization in younger eyes. Inherited macular dystrophies, including pattern dystrophy, can mimic AMD in people in their 40s and 50s.

Misdiagnosis in the other direction, missing wet AMD, usually happens when distortion is attributed to cataract, to a change in glasses prescription or simply to aging. Because the other eye compensates, the person may not report a problem at all.

Modern imaging has sharply reduced these errors. OCT shows the retinal layers in cross-section and distinguishes fluid under the retina from a hole, swelling or atrophy; angiography maps leaking vessels. If a diagnosis was made without these scans, or if vision keeps changing despite a reassuring label, asking for repeat imaging or a retina-specialist opinion is reasonable and routine. A second look is not an accusation; it is how retinal diagnosis is meant to work.

Living with central vision loss: what everyday life looks like

Here is where the “spared peripheral vision” fact turns practical. Because side vision remains, most people with advanced AMD continue to walk independently, manage their homes and recognize people by gait, voice and outline. What becomes hard is anything requiring fine central detail: reading small print, threading a needle, seeing facial expressions, reading road signs at distance.

Low-vision services exist precisely for this gap, and the Mayo Clinic and NHS both recommend them. Magnifiers, from simple handheld lenses to electronic devices that enlarge text on a screen, make print accessible again. Large-print and audio books, high-contrast kitchen tools, strong task lighting positioned to the side, and talking clocks and scales reduce daily friction. Phone and tablet accessibility settings, including large text, screen readers and high-contrast modes, are free and underused.

Eccentric viewing is a learned skill in which the person deliberately looks slightly to one side of what they want to see, placing the image on healthier retina just outside the damaged center. Occupational therapists and low-vision specialists can teach it; it feels unnatural at first and useful within weeks for many people.

Driving is the question families argue about most. Legal standards rest on measured acuity and visual field, which an eye clinician can test; the decision should follow those measurements rather than assumptions.

One phenomenon deserves naming because it alarms people who have never heard of it. Charles Bonnet syndrome is the experience of seeing vivid patterns, faces or scenes that are not there, occurring in people with significant sight loss whose minds are otherwise sound. The NHS describes it as a common and benign response of the brain to reduced visual input, not a sign of dementia or psychiatric illness. Knowing it exists spares a great deal of unnecessary fear.

Questions to ask your care team

A good consultation is a conversation, and specific questions get specific answers. These are the ones retina clinicians say they wish more patients asked.

• Which stage of AMD do I have in each eye, and is it dry, wet or both?
• What did my OCT scan show, and can you point out what you are watching for on the image?
• How often do you want to see me, and what would make you want to see me sooner?
• Should I be using an Amsler grid or another home check, and exactly how should I do it?
• Am I in the group for whom the AREDS2 formula has evidence, and does my smoking history change that advice?
• If I need injections, how will you decide how often, and what signs between appointments mean I should call rather than wait?
• What would you expect my vision to look like in a year if the disease follows its usual course, and what would change that?
• Is there anything about my diagnosis that makes you want a second opinion or additional imaging?
• Can you refer me to a low-vision service, and at what point would that be useful?
• Do I still meet the visual standard for driving, and how will we check that over time?
• Are there clinical trials I might be eligible for, and how would I find out about them responsibly?

Bringing a companion to take notes helps, because dilated pupils make reading your own handwriting difficult afterward. Asking for a printed or emailed summary is reasonable. So is asking the clinician to say, in one sentence, what the single most important thing for you to do before the next visit is. For many people the answer will be “stop smoking”; for others it will be “check the grid weekly”; for someone with wet disease it will be “do not miss the next injection.” Knowing which applies to you is worth more than any general advice.

When to call your doctor

Most of AMD unfolds slowly, which is why the exceptions matter so much. Certain changes signal possible conversion to wet disease or another retinal emergency, and the response time that protects vision is days, not the next scheduled appointment.

Contact your eye clinic or seek urgent eye care the same day if you notice any of the following in either eye, especially if it is new or has appeared over hours to days:

• Straight lines, such as door frames or the lines on an Amsler grid, suddenly look bent, wavy or broken.
• A new blank, gray or dark patch appears in the center of your vision, or an existing one grows noticeably.
• Printed words or faces suddenly seem smaller, larger or distorted in one eye compared with the other.
• A rapid drop in vision in one eye, discovered when you happen to cover the other.
• A shower of new floaters, flashes of light, or a curtain or shadow moving across your side vision; these can indicate a retinal tear or detachment, a separate emergency.
• After an eye injection: increasing pain, worsening redness, sensitivity to light, or vision that gets worse rather than better over the following days. These can be early signs of infection inside the eye and require immediate assessment.

Call during normal hours, without the same urgency, if you notice gradual fading of colors, a growing need for brighter light to read, or increasing difficulty with faces over weeks, so the team can bring your review forward.

The Mayo Clinic and NHS both emphasize that sudden changes in central vision should be assessed promptly because treatment for wet AMD works best before scarring develops. If you cannot reach your usual clinic, an emergency department or urgent eye service can examine the retina. Whatever you find, the decision about treatment rests with the clinician who can see your scan; your job is to make sure they see it in time.

Frequently asked questions

Does macular degeneration cause blindness in everyone who has it?

No. Most people with age-related macular degeneration have the early or intermediate stage and keep normal or near-normal vision. Even advanced disease typically spares peripheral vision, so people retain the ability to move around and see shapes and movement. Severe central loss can meet legal definitions of sight impairment, which is where the confusion arises, but complete loss of light perception from AMD alone is not the expected course described by the NHS or the National Eye Institute.

How many people have macular degeneration?

The National Eye Institute identifies AMD as a leading cause of vision loss in Americans over 50, and widely cited US estimates put the number of adults with some form of the condition at roughly 20 million, most of them at the early stage with no noticeable symptoms. Prevalence rises sharply after age 75. The NHS describes it as a common condition that usually first appears in people in their 50s and 60s, with numbers expected to grow as populations age.

Why are carrots said to be good for your eyes?

Carrots are rich in beta-carotene, which the body converts to vitamin A, a nutrient essential for the light-sensing pigment in the retina. Vitamin A deficiency genuinely causes night blindness, so in populations short of the vitamin carrots protect sight. For people already eating a varied diet, extra carrots do not sharpen vision or prevent macular degeneration. The AREDS2 trial actually removed beta-carotene from its formula because of lung cancer risk in smokers, favoring lutein and zeaxanthin from leafy greens instead.

What eye condition starts with the letter M besides macular degeneration?

Several, and they are often confused with one another. Macular edema is swelling of the macula from fluid, commonly linked to diabetes or a blocked retinal vein. A macular hole is a small defect in the center of the macula, usually treated surgically. Myopic degeneration affects people with very high short-sightedness. Myopia itself is simple short-sightedness. Each causes central blur or distortion, which is why imaging rather than symptoms alone is used to tell them apart.

Is macular degeneration ever misdiagnosed?

Yes, in both directions. Conditions such as central serous chorioretinopathy, macular edema, macular hole and inherited macular dystrophies can be labeled AMD, while early wet AMD is sometimes attributed to cataract or a change in glasses. Optical coherence tomography, a cross-sectional retinal scan, and angiography have made these errors far less common. If a diagnosis was made without imaging or vision keeps changing despite a reassuring label, requesting repeat scans or a retina-specialist opinion is routine and reasonable.

Is macular degeneration hereditary?

Family history is an established risk factor, and researchers have identified more than twenty genetic variants linked to the condition, most notably in the complement factor H gene and the ARMS2 region. Having an affected parent or sibling raises your probability but does not make the disease inevitable, and many people with AMD have no affected relatives. Routine genetic testing is not currently recommended because the result would not change the advice, which is regular eye examinations, not smoking, and a healthy diet.

What is the difference between wet vs dry macular degeneration?

Dry AMD is the slow form, in which waste deposits called drusen accumulate and the supporting cell layer thins over years; it accounts for most cases. Wet AMD is the faster form, in which abnormal blood vessels grow under the retina and leak fluid or blood, potentially damaging central vision within weeks. Wet disease develops in eyes that already have dry changes and is the form treated with anti-VEGF injections, which is why people with dry AMD are asked to watch for new distortion.

Can macular degeneration be stopped or reversed?

No established treatment restores a macula to its pre-disease state. Anti-VEGF injections for wet AMD can halt leakage, stabilize vision and in some cases recover sight lost to recent fluid; the NHS describes treatment as ongoing rather than a single course. For intermediate dry AMD, the AREDS2 supplement formula reduced progression to late disease by about 25 percent over five years in the NIH trial. Whether and when to start either belongs with the treating ophthalmologist.

Do reading, screens or dim light make macular degeneration worse?

No. Using your eyes does not wear out the retina or speed up cell loss, a point both the NHS and the Mayo Clinic make explicitly. Reading in dim light or long hours at a screen may cause temporary tiredness or dryness but has no demonstrated effect on AMD progression. Good lighting is recommended simply because it makes remaining vision easier to use, not because darkness is harmful. Blue-light filtering lenses have not been shown to prevent or slow the disease.

What are the early signs of macular degeneration that should prompt an eye exam?

Early AMD often causes no symptoms at all and is found at a routine dilated examination, which is why eye-health bodies recommend regular checks after 50. When changes do appear they tend to involve central vision: straight lines looking slightly wavy, print needing brighter light, colors seeming faded, or a soft blur in the middle of what you look at. Any of these, especially in one eye, warrants an appointment; a sudden change warrants a same-day call.

References

• National Eye Institute (NIH): Age-Related Macular Degeneration (AMD)
• National Eye Institute (NIH): Age-Related Eye Disease Studies (AREDS/AREDS2)
• NHS: Age-related macular degeneration (AMD)

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.